Given amivantamab’s strong affinity for the MET receptor and the role of MET amplification as a driver of resistance to third-generation EGFR-TKIs, the combination of amivantamab and EGFR-TKI lazertinib was investigated in EGFR-mutant, osimertinib-resistant, chemotherapy-naïve NSCLC patients in the phase 1 CHRYSALIS trial [84]. Here, EGFR is linked to non-small cell lung carcinoma.